EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma

Kosuke Suzuki, Yumi Otoyama, Natsumi Matsumoto, Yusuke Masuo, Yoko Nakajima, Ikuya Sugiura, Takahiro Fuji, Erika Nomura, Yuki Ichikawa, Yuu Shimozuma, Manabu Uchikoshi, Momoka Hayano und 8 weitere

Clinical Pharmacokinetics · 2026-08 · 65 (8) · 1229-1241

DOI: 10.1007/s40262-026-01662-0 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 23.06.2026. Verfasst von Kosuke Suzuki und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmaceutics, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Bilirubin, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science London, SHOWA Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBilirubinCarcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesSerum AlbuminAgedAged, 80 and overFemaleHumansMaleMiddle AgedArea Under CurveJapanProgression-Free SurvivalProspective StudiesEast Asian People

Substanzen

Antineoplastic AgentsBilirubinlenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesSerum Albumin

Autor:innen und Institutionen

  • Department of Hospital Pharmaceutics, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
  • Division of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
  • Department of Cancer Genome and Pharmacotherapy, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
  • Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
  • Laboratory of Molecular Pharmacotherapeutics, Faculty of Pharmacy, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.
  • Department of Cancer Genome and Pharmacotherapy, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan. k.fujita@med.showa-u.ac.jp.

Förderung

  • Japan Society for the Promotion of Science London
  • SHOWA Medical University

Zitieren

APA

Suzuki, K., Otoyama, Y., Matsumoto, N., Masuo, Y., Nakajima, Y., Sugiura, I., Fuji, T., Nomura, E., Ichikawa, Y., Shimozuma, Y., Uchikoshi, M., Hayano, M., Hanano, M., Murase, R., Mitomori, C., Oka, K., Sakaki, M., Kato, Y., Yoshida, H., & Fujita, K. I. (2026). ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma. Clinical Pharmacokinetics, 65(8), 1229-1241. https://doi.org/10.1007/s40262-026-01662-0

Vancouver

Suzuki K, Otoyama Y, Matsumoto N, Masuo Y, Nakajima Y, Sugiura I, et al. ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma. Clinical Pharmacokinetics. 2026;65(8):1229-1241. doi:10.1007/s40262-026-01662-0

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Kosuke and Otoyama, Yumi and Matsumoto, Natsumi and Masuo, Yusuke and Nakajima, Yoko and Sugiura, Ikuya and Fuji, Takahiro and Nomura, Erika and Ichikawa, Yuki and Shimozuma, Yuu and Uchikoshi, Manabu and Hayano, Momoka and Hanano, Mayuko and Murase, Remi and Mitomori, Chika and Oka, Kiyoshi and Sakaki, Masashi and Kato, Yukio and Yoshida, Hitoshi and Fujita, Ken-Ichi},
  title = {ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {8},
  pages = {1229--1241},
  doi = {10.1007/s40262-026-01662-0}
}
Kostenlos starten →